BlackRock Capital Investment Corporation (BKCC) Tops Q2 EPS by 1c
Get Alerts BKCC Hot Sheet
Join SI Premium – FREE
BlackRock Capital Investment Corporation (NASDAQ: BKCC) reported Q2 EPS of $0.07, $0.01 better than the analyst estimate of $0.06.
- GAAP Net Investment Income (“NII”) of $0.07 per share, or $4.8 million, was up 15.6% from the first quarter, which provided second quarter distribution coverage of 65%, an improvement from 56% in the first quarter.
- Net Asset Value (“NAV”) increased to $347.2 million, up 7.5% from $322.9 million at the end of the first quarter of 2021; NAV per share increased 7.6% to $4.68 per share from $4.35 per share, primarily due to net realized and unrealized gains of $27.2 million during the quarter.
- Strong gross deployments in senior secured debt of $88.9 million with sixteen new portfolio companies added, and further progress towards reducing junior capital and non-core exposure including previously disclosed exit on Red Apple.
- Net leverage of 0.56x as of June 30, 2021, up from 0.38x as of March 31, 2021, primarily driven by net deployments during the current quarter.
- Total liquidity for portfolio company investments, including cash, was approximately $230 million, subject to leverage and borrowing base restrictions.
- Under the existing share repurchase program, 80,944 shares were repurchased during the second quarter for approximately $0.3 million at an average price of $3.73 per share, including brokerage commissions.
- Subsequent to June 30, 2021, the Company exited its equity investment in SVP-Singer Holdings LP (“SVP”), a non-core legacy portfolio company, as a result of the sale of SVP. The exit resulted in $19.6 million of cash proceeds and newly issued equity with a cost basis of approximately $6 million.
For earnings history and earnings-related data on BlackRock Capital Investment Corporation (BKCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share